Outset Medical, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

OM$4.22+2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity

Convertible Preferred Stock · Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance as of December 31, 2025	—	$—	18,169	$18	$1,298,138	$172	$(1,171,376)	$126,952
Issuance of common stock through employee stock purchase plan	—	—	170	—	506	—	—	506
Issuance of common stock for settlement of RSUs	—	—	190	—	—	—	—	—
Stock-based compensation expense	—	—	—	—	3,453	—	—	3,453
Unrealized loss on available-for-sale securities	—	—	—	—	—	(245)	—	(245)
Net loss	—	—	—	—	—	—	(18,978)	(18,978)
Balance as of March 31, 2026	—	$—	18,529	$18	$1,302,097	$(73)	$(1,190,354)	$111,688
Issuance of common stock for settlement of RSUs	—	—	268	1	(1)	—	—	—
Stock-based compensation expense	—	—	—	—	2,696	—	—	2,696
Unrealized loss on available-for-sale securities	—	—	—	—	—	(63)	—	(63)
Net loss	—	—	—	—	—	—	(17,984)	(17,984)
Balance as of June 30, 2026	—	$—	18,797	$19	$1,304,792	$(136)	$(1,208,338)	$96,337
Issuance of common stock through employee stock purchase plan	—	—	28	—	83	—	—	83
Issuance of common stock for settlement of RSUs	—	—	48	—	—	—	—	—
Stock-based compensation expense	—	—	—	—	1,688	—	—	1,688
Unrealized loss on available-for-sale securities	—	—	—	—	—	(108)	—	(108)
Net loss	—	—	—	—	—	—	(14,686)	(14,686)
Balance as of September 30, 2026	—	$—	18,873	$19	$1,306,563	$(244)	$(1,223,024)	$83,314

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity

Convertible Series A Preferred Stock · Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders'
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance as of December 31, 2024	—	$—	3,530	$4	$1,116,496	$42	$(1,089,723)	$26,819
Issuance of Series A convertible preferred stock, net of issuance costs	863	161,071	—	—	—	—	—	161,071
Conversion of convertible preferred stock to common stock	(842)	(157,230)	14,046	14	157,216	—	—	—
Issuance of common stock warrant, net of issuance costs	—	—	—	—	4,330	—	—	4,330
Issuance of common stock through employee stock purchase plan	—	—	60	—	408	—	—	408
Issuance of common stock for settlement of RSUs	—	—	86	—	—	—	—	—
Stock-based compensation expense	—	—	—	—	2,977	—	—	2,977
Unrealized gain on available-for-sale securities	—	—	—	—	—	46	—	46
Net loss	—	—	—	—	—	—	(25,783)	(25,783)
Balance as of March 31, 2025	21	$3,841	17,722	$18	$1,281,427	$88	$(1,115,506)	$169,868
Issuance of common stock for settlement of RSUs	—	—	44	—	—	—	—	—
Stock-based compensation expense	—	—	—	—	3,496	—	—	3,496
Unrealized loss on available-for-sale securities	—	—	—	—	—	(39)	—	(39)
Net loss	—	—	—	—	—	—	(18,541)	(18,541)
Balance as of June 30, 2025	21	$3,841	17,766	$18	$1,284,923	$49	$(1,134,047)	$154,784
Issuance of common stock through employee stock purchase plan	—	—	27	—	231	—	—	231
Issuance of common stock for settlement of RSUs	—	—	16	—	—	—	—	—
Stock-based compensation expense	—	—	—	—	5,080	—	—	5,080
Unrealized gain on available-for-sale securities	—	—	—	—	—	108	—	108
Net loss	—	—	—	—	—	—	(17,838)	(17,838)
Balance as of September 30, 2025	21	$3,841	17,809	$18	$1,290,234	$157	$(1,151,885)	$142,365

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.